NASDAQ:IMMU - Immunomedics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$22.35 +1.00 (+4.68 %)
(As of 10/18/2018 09:19 AM ET)
Previous Close$21.35
Today's Range$21.35 - $22.4950
52-Week Range$8.68 - $27.33
Volume1.93 million shs
Average Volume2.15 million shs
Market Capitalization$3.89 billion
P/E Ratio-21.70
Dividend YieldN/A
Beta1.85
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer; and a collaboration agreement with Yale Cancer Center to evaluate its ADC product as a single agent in two phase II studies in patients with persistent or recurrent endometrial and cervical cancers. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMMU
CUSIP45290710
Phone973-605-8200

Debt

Debt-to-Equity Ratio0.05
Current Ratio14.83
Quick Ratio14.83

Price-To-Earnings

Trailing P/E Ratio-21.70
Forward P/E Ratio-20.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.16 million
Price / Sales1,933.17
Cash FlowN/A
Price / CashN/A
Book Value$2.39 per share
Price / Book9.35

Profitability

EPS (Most Recent Fiscal Year)($1.03)
Net Income$-273,830,000.00
Net Margins-12,701.21%
Return on Equity-124.54%
Return on Assets-38.70%

Miscellaneous

Employees185
Outstanding Shares186,830,000
Market Cap$3.89 billion

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) released its earnings results on Thursday, August, 23rd. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.46. The biopharmaceutical company earned $0.40 million during the quarter, compared to analyst estimates of $4.27 million. Immunomedics had a negative net margin of 12,701.21% and a negative return on equity of 124.54%. The business's revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.48) earnings per share. View Immunomedics' Earnings History.

When is Immunomedics' next earnings date?

Immunomedics is scheduled to release their next quarterly earnings announcement on Thursday, November 8th 2018. View Earnings Estimates for Immunomedics.

What price target have analysts set for IMMU?

5 equities research analysts have issued 1-year target prices for Immunomedics' shares. Their forecasts range from $27.00 to $55.00. On average, they expect Immunomedics' stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 74.5% from the stock's current price. View Analyst Price Targets for Immunomedics.

What is the consensus analysts' recommendation for Immunomedics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest during the month of September. As of September 28th, there was short interest totalling 19,884,011 shares, an increase of 10.9% from the September 14th total of 17,928,831 shares. Based on an average daily volume of 1,727,201 shares, the days-to-cover ratio is currently 11.5 days. Approximately 11.9% of the shares of the company are short sold. View Immunomedics' Current Options Chain.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:
  • Mr. Michael R. Garone, CFO, Principal Accounting Officer & VP of Fin. (Age 59)
  • Mr. Michael F. Pehl, Pres, CEO & Director (Age 53)
  • Ms. Phyllis Parker, Director of Admin.
  • Dr. Chau Cheng, Sr. Director of Investor Relations & Corp. Sec.
  • Dr. William A. Wegener, Chief Medical Officer

Who are Immunomedics' major shareholders?

Immunomedics' stock is owned by many different of institutional and retail investors. Top institutional investors include Deprince Race & Zollo Inc. (0.01%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

Which institutional investors are buying Immunomedics stock?

IMMU stock was bought by a variety of institutional investors in the last quarter, including Deprince Race & Zollo Inc.. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $22.35.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $3.89 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 185 workers across the globe.

What is Immunomedics' official website?

The official website for Immunomedics is http://www.immunomedics.com.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]


MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  498
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel